47. バージャー病 Disease details / Clinical trials / Drug dev / DR info

臨床試験数 : 14 / 薬物数 : 18 - (DrugBank : 13) / 標的遺伝子数 : 7 - 標的パスウェイ数 : 19

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
Adult human bone marrow derived, cultured, pooled, allogeneic mesenchymal stromal cells
   Cell Biopeutics Resources Sdn Bhd
      2024   Phase 4   NCT05854615   Malaysia
Allogeneic mesenchymal stem cells
   Stempeutics Research Pvt Ltd
      2012   Phase 2   NCT01484574   India
Basic fibroblast growth factor
   Kyoto University Graduate School of Medicine Department of Cardiovascular Surgery
      2009   -   JPRN-UMIN000002671   Japan
Bosentan
   Hospital Universitario Getafe
      2009   -   NCT01447550   Spain
Botox injection
   University Hospital, Toulouse
      2025   Phase 3   NCT05698979   -
Botulinum toxin type A
   CHU de Toulouse
      2022   Phase 4   EUCTR2021-005723-20-FR   France
CLBS12
   EPS Corporation (Global Sponsor: Caladrius Biosciences, Inc.)
      2017   -   JPRN-jRCT1080223694   Japan
   Lisata Therapeutics, Inc.
      2017   Phase 2   NCT02501018   Japan
Erythropoietin
   EVEETA Study Group
      2016   -   JPRN-UMIN000021374   Japan
Filgrastim
   Kenichi Yamahara
      2024   Phase 1   JPRN-jRCT2052230115   -
G-CSF
   Kenichi Yamahara
      2024   Phase 1   JPRN-jRCT2052230115   -
   Regenerative Medicine Unit, Division of Vascular Regeneration Therapy, Institute of Biomedical Research and Innovation (IBRI)
      2011   -   JPRN-UMIN000005227   Japan
Gelatin
   Kyoto University Graduate School of Medicine Department of Cardiovascular Surgery
      2009   -   JPRN-UMIN000002671   Japan
   The University of Tokyo Hospital
      2004   -   JPRN-C000000200   Japan
Ginkgo biloba
   First Clinical Center of Chinese PLA General Hospital
      2021   Phase 0   ChiCTR2100048104   China
Heparin
   First Clinical Center of Chinese PLA General Hospital
      2021   Phase 0   ChiCTR2100048104   China
Platelet rich plasma
   EVEETA Study Group
      2016   -   JPRN-UMIN000021374   Japan
Selexipag
   Actelion
      2021   -   NCT04914247   -
SOC
   Lisata Therapeutics, Inc.
      2017   Phase 2   NCT02501018   Japan
Thrombopoietin
   EVEETA Study Group
      2016   -   JPRN-UMIN000021374   Japan
Trafermin
   The University of Tokyo Hospital
      2004   -   JPRN-C000000200   Japan